Heritas Capital co-leads Hummingbird Bioscience's extended Series A

Heritas Capital co-leads Hummingbird Bioscience's extended Series A

Antibody visual sourced from Hummingbird's website

Biotech company Hummingbird Bioscience has announced the completion of an extended Series A funding round led by Singapore-based Heritas Capital Management and SEEDS Capital, the investment arm of Enterprise Singapore.

Existing backer and Series A lead investor Decheng Capital also participated in the latest financing.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter